Buffett's Exit Amplifies Skepticism on BAC's Net Interest Income Defense

What happened

Warren Buffett sold 50% of his Bank of America stake through Berkshire Hathaway in the quarters leading up to his December 2025 retirement, as shown in Form 13Fs. This divestment coincides with a critical phase for BAC, where net interest income (NII) faces pressure from Federal Reserve easing, with a -100 bps rate shock posing a ~$2.0B pretax headwind per the 2026 10-K. Management's guidance targets deposit beta reaching the low-70s by end-1Q26 to stabilize NII, a key operational checkpoint highlighted in the DeepValue report. Buffett's reduced position, from a historically long-term holder, signals potential doubt in BAC's execution amid these margin challenges and political risks like credit-card APR caps. The sale reinforces market narratives that focus on rates and regulation, adding sentiment overhang to BAC's already uncertain earnings trajectory.

Implication

Investors should view Buffett's sale as a cautionary signal that aligns with the DeepValue report's emphasis on deposit beta as a critical catalyst for NII stability. If BAC fails to meet its low-70s target by end-1Q26, NII could decline, validating Buffett's move and pressuring the stock toward the report's bear-case value of $40. However, the report notes BAC's strong capital return program, with $30.1B in buyback authorization and stable credit metrics, which could support per-share value if execution holds. Political risks, such as potential credit-card APR caps, add further uncertainty that Buffett may be avoiding, though legislative traction remains weak. Overall, this development underscores the need for disciplined monitoring of 1Q26 deposit beta disclosure and NII sensitivity updates before making investment decisions.

Thesis delta

Buffett's sale introduces a negative sentiment shift but does not alter the fundamental thesis that BAC's investment case hinges on deposit beta execution and NII stabilization. However, it adds a near-term overhang that could depress valuation if investor confidence erodes further, especially if upcoming catalysts disappoint. The core potential buy thesis remains data-dependent, but now faces increased scrutiny from a high-profile exit.